New strategy for gastrointestinal protection based on gaseous mediators application
The aim of review. To assess protective mechanisms and efficacy of gaseous mediators based antiinflammatory therapy. Key points. Nowadays there are no reasonable and effective methods of prevention and treatment of NSAID-induced intestinal lesions. The discovery of powerful anti-inflammatory and cyt...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2018-08-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/56 |
| Summary: | The aim of review. To assess protective mechanisms and efficacy of gaseous mediators based antiinflammatory therapy. Key points. Nowadays there are no reasonable and effective methods of prevention and treatment of NSAID-induced intestinal lesions. The discovery of powerful anti-inflammatory and cytoprotective effects of endogenous gaseous mediators (nitric oxide, hydrogen sulfide, carbon monoxide) led to development of new combined nonsteroidal anti-inflammatory drugs (NSAIDs), which in addition to cyclooxygenase inhibitor include gas-releasing molecules. One of such molecules is hydrogen sulfide (H2S) - the gaseous mediator that is produced under physiological conditions. H2S provides a powerful cytoprotective, antiinflammatory and antioxidant effects, optimizes the intestinal microbiota and improves gastroinesinal protection directly and through stimulation of other cytoprotectors, including prostaglandins, carbon monoxide and nitric oxide. Conclusion. Application of H2S-releasing NSAIDs provides powerful protection of the gastrointestinal tract, while maintaining and/or enhancing the antiinflammatory effect. H2S-releasing anti-inflammatory drugs show considerable promise as a safer option for treating chronic inflammatory diseases. |
|---|---|
| ISSN: | 1382-4376 2658-6673 |